Fig. 5.
Fig. 5. Kaplan-Meier analysis of cumulative survival of mice bearing Ramos lymphoma xenografts treated with pretargeted radioimmunotherapy. / Groups of 10 mice bearing approximately 100 mm3 Ramos tumor xenografts were treated as described in the legend to Figure 4 and analyzed for survival as a function of time. Treatment groups included mice treated with (1) 1.4 nmol BC8-SA conjugate, followed 20 hours later by 5.8 nmol clearing agent, and 2 hours after that with 800 μCi (29.6 MBq) (A), 400 μCi (14.8 MBq) (B), or 200 μCi (7.4 MBq) (C)90Y-DOTA-biotin or (2) 1.4 nmol 1F5-SA conjugate, followed 20 hours later by 5.8 nmol clearing agent and 2 hours after that with 800 μCi (29.6 MBq) (D), 400 μCi (14.8 MBq) (E), and 200 μCi (7.4 MBq) (F) of 90Y-DOTA-biotin. The letters A-F in this figure correspond to treatment groups designated in panels A-F in Figure4.

Kaplan-Meier analysis of cumulative survival of mice bearing Ramos lymphoma xenografts treated with pretargeted radioimmunotherapy.

Groups of 10 mice bearing approximately 100 mm3 Ramos tumor xenografts were treated as described in the legend to Figure 4 and analyzed for survival as a function of time. Treatment groups included mice treated with (1) 1.4 nmol BC8-SA conjugate, followed 20 hours later by 5.8 nmol clearing agent, and 2 hours after that with 800 μCi (29.6 MBq) (A), 400 μCi (14.8 MBq) (B), or 200 μCi (7.4 MBq) (C)90Y-DOTA-biotin or (2) 1.4 nmol 1F5-SA conjugate, followed 20 hours later by 5.8 nmol clearing agent and 2 hours after that with 800 μCi (29.6 MBq) (D), 400 μCi (14.8 MBq) (E), and 200 μCi (7.4 MBq) (F) of 90Y-DOTA-biotin. The letters A-F in this figure correspond to treatment groups designated in panels A-F in Figure4.

Close Modal

or Create an Account

Close Modal
Close Modal